# EDGAR Filing Document

**Accession Number:** 0001939329
**File Stem:** 0000899140-26-000140
**Filing Date:** 2026-2
**Character Count:** 26813
**Document Hash:** 7ebdbfc4fa9b3571982b86b85195a708
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899140-26-000140.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0000899140-26-000140

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260204

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** SUVRETTA CAPITAL MANAGEMENT, LLC
- **CENTRAL INDEX KEY:** 0001569064

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43097
- **FILM NUMBER:** 26612893

**BUSINESS ADDRESS:**
- **STREET 1:** 540 MADISON AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 2127025204

**MAIL ADDRESS:**
- **STREET 1:** 540 MADISON AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Cowen Aaron
- **CENTRAL INDEX KEY:** 0001869640

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43097
- **FILM NUMBER:** 26612892

**MAIL ADDRESS:**
- **STREET 1:** 540 MADISON AVENUE, 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Averill Madison Master Fund, Ltd.
- **CENTRAL INDEX KEY:** 0002021243

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43097
- **FILM NUMBER:** 26612890

**BUSINESS ADDRESS:**
- **STREET 1:** C/O SUVRETTA CAPITAL MANAGEMENT, LLC
- **STREET 2:** 540 MADISON AVENUE, 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-702-5205

**MAIL ADDRESS:**
- **STREET 1:** C/O SUVRETTA CAPITAL MANAGEMENT, LLC
- **STREET 2:** 540 MADISON AVENUE, 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Averill Master Fund, Ltd.
- **CENTRAL INDEX KEY:** 0001939329

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43097
- **FILM NUMBER:** 26612891

**BUSINESS ADDRESS:**
- **STREET 1:** C/O SUVRETTA CAPITAL MANAGEMENT, LLC
- **STREET 2:** 540 MADISON AVENUE, 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-702-5205

**MAIL ADDRESS:**
- **STREET 1:** C/O SUVRETTA CAPITAL MANAGEMENT, LLC
- **STREET 2:** 540 MADISON AVENUE, 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veradermics, Inc
- **CENTRAL INDEX KEY:** 0001827635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843304423
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513
- **BUSINESS PHONE:** 228.372.3376

**MAIL ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VeraDermics, Inc
- **DATE OF NAME CHANGE:** 20201008

## Exhibit 99.1

#### Exhibit 99.1

<u>Explanation of Responses</u>:

(1) This Form 4 is filed on behalf of Averill Master Fund, Ltd., a Cayman Islands exempted company ("Averill Master Fund"), Averill
 Madison Master Fund, Ltd., a Cayman Islands exempted company ("Averill Madison Master Fund" and, together with the Averill Master Fund, the "Funds"), Suvretta Capital Management, LLC, a Delaware limited liability company ("Suvretta Capital"),
 and Aaron Cowen ("Mr. Cowen") (collectively, the "Reporting Persons"). Suvretta Capital is the investment manager of the Funds. Mr. Cowen may be deemed to control Suvretta Capital and therefore may be deemed to beneficially own shares of
 Common Stock (as defined below) held by the Funds. Mr. Cowen disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any indirect pecuniary interest therein. The securities reported herein are
 directly held by either Averill Master Fund or Averill Madison Master Fund as noted herein. Each of the Funds and Suvretta Capital may be deemed a director by deputization by virtue of David Friedman, M.D., a Managing Director and Senior
 Analyst at Suvretta Capital, serving on the board of directors of the Issuer (as defined below).

(2) The price reported in column 4 is a weighted average price. These shares of common stock, par value $0.00001 per share (the "Common
 Stock"), of Veradermics, Incorporated (the "Issuer") were purchased by Averill Master Fund in multiple open market transactions at prices ranging from $33.50 to $34.50 per share. The Reporting Persons undertake to provide to the Issuer, any
 security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(3) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Master Fund in
 multiple open market transactions at prices ranging from $34.53 to $35.42 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(4) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Master Fund in
 multiple open market transactions at prices ranging from $35.55 to $36.55 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(5) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Master Fund in
 multiple open market transactions at prices ranging from $36.56 to $37.56 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(6) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Master Fund in
 multiple open market transactions at prices ranging from $37.57 to $38.57 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(7) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Master Fund in
 multiple open market transactions at prices ranging from $38.58 to $39.50 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(8) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $33.50 to $34.50 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(9) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $34.53 to $35.42 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(10) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $35.55 to $36.55 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(11) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $36.56 to $37.56 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(12) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $37.57 to $38.57 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(13) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $38.58 to $39.50 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(14) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $35.14 to $36.14 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(15) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $36.18 to $37.18 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(16) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $37.19 to $38.18 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(17) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $38.20 to $39.20 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(18) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $39.21 to $40.00 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(19) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $35.26 to $36.26 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(20) The price reported in column 4 is a weighted average price. These shares of Common Stock were purchased by Averill Madison Master Fund
 in multiple open market transactions at prices ranging from $36.26 to $37.26 per share. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon
 request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

## Exhibit 99.2

Exhibit 99.2

#### Joint Filer Information

Joint Filers:

---

| | |
|:---|:---|
| 1. Name: | Aaron Cowen |
| Address: | c/o Suvretta Capital Management, LLC |
|  | 540 Madison Avenue, 7th Floor |
|  | New York, NY 10022 |
| 2. Name: | Averill Master Fund, Ltd. |
| Address: | c/o Suvretta Capital Management, LLC |
|  | 540 Madison Avenue, 7th Floor |
|  | New York, NY 10022 |
| 3. Name: | Averill Madison Master Fund, Ltd. |
| Address: | c/o Suvretta Capital Management, LLC |
|  | 540 Madison Avenue, 7th Floor |
|  | New York, NY 10022 |

---

## Exhibit 99.3

Exhibit 99.3

#### Joint Filers' Signatures

---

| | |
|:---|:---|
| AVERILL MASTER FUND, LTD. |  |
| By: <u>/s/ Andrew Nathanson</u>  | <u>Date: February 9, 2026</u> |
| Name: Andrew Nathanson |  |
| Title: Authorized Signatory |  |
| AVERILL MADISON MASTER FUND, LTD. |  |
| By: <u>/s/ Andrew Nathanson</u>  | <u>Date: February 9, 2026</u> |
| Name: Andrew Nathanson |  |
| Title: Authorized Signatory |  |
| By:<u> </u><u>/s/ Aaron Cowen</u>  | <u>Date: February 9, 2026</u> |
| Name: Aaron Cowen |  |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>SUVRETTA CAPITAL MANAGEMENT, LLC<br><sub>(Last) (First) (Middle)</sub><br>540 MADISON AVENUE<br>7TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Veradermics, Inc [ MANE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Cowen Aaron<br><sub>(Last) (First) (Middle)</sub><br>C/O SUVRETTA CAPITAL MANAGEMENT, LLC<br>540 MADISON AVENUE, 7TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Veradermics, Inc [ MANE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Averill Master Fund, Ltd.<br><sub>(Last) (First) (Middle)</sub><br>C/O SUVRETTA CAPITAL MANAGEMENT, LLC<br>540 MADISON AVENUE, 7TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Veradermics, Inc [ MANE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Averill Madison Master Fund, Ltd.<br><sub>(Last) (First) (Middle)</sub><br>C/O SUVRETTA CAPITAL MANAGEMENT, LLC<br>540 MADISON AVENUE, 7TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10022<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Veradermics, Inc [ MANE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 10004<sup>(2)</sup> | A | 34.25<sup>(2)</sup> | 3525462 | I<sup>(1)</sup> | See footnotes<sup>(1)(2)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 10676<sup>(3)</sup> | A | 34.74<sup>(3)</sup> | 3536138 | I<sup>(1)</sup> | See footnotes<sup>(1)(3)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 14659<sup>(4)</sup> | A | 36.27<sup>(4)</sup> | 3550797 | I<sup>(1)</sup> | See footnotes<sup>(1)(4)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 53344<sup>(5)</sup> | A | 37.11<sup>(5)</sup> | 3604141 | I<sup>(1)</sup> | See footnotes<sup>(1)(5)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 25908<sup>(6)</sup> | A | 38.09<sup>(6)</sup> | 3630049 | I<sup>(1)</sup> | See footnotes<sup>(1)(6)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 18489<sup>(7)</sup> | A | 38.9<sup>(7)</sup> | 3648538 | I<sup>(1)</sup> | See footnotes<sup>(1)(7)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 1720<sup>(8)</sup> | A | 34.25<sup>(8)</sup> | 372579 | I<sup>(1)</sup> | See footnotes<sup>(1)(8)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 1835<sup>(9)</sup> | A | 34.74<sup>(9)</sup> | 374414 | I<sup>(1)</sup> | See footnotes<sup>(1)(9)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 2519<sup>(10)</sup> | A | 36.27<sup>(10)</sup> | 376933 | I<sup>(1)</sup> | See footnotes<sup>(1)(10)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 9168<sup>(11)</sup> | A | 37.11<sup>(11)</sup> | 386101 | I<sup>(1)</sup> | See footnotes<sup>(1)(11)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 4453<sup>(12)</sup> | A | 38.09<sup>(12)</sup> | 390554 | I<sup>(1)</sup> | See footnotes<sup>(1)(12)</sup> |
| Common stock, par value $01 per share | 2026-02-04 |  | P |  | 3178<sup>(13)</sup> | A | 38.9<sup>(13)</sup> | 393732 | I<sup>(1)</sup> | See footnotes<sup>(1)(13)</sup> |
| Common stock, par value $01 per share | 2026-02-05 |  | P |  | 3832<sup>(14)</sup> | A | 36.07<sup>(14)</sup> | 397564 | I<sup>(1)</sup> | See footnotes<sup>(1)(14)</sup> |
| Common stock, par value $01 per share | 2026-02-05 |  | P |  | 19199<sup>(15)</sup> | A | 36.93<sup>(15)</sup> | 416763 | I<sup>(1)</sup> | See footnotes<sup>(1)(15)</sup> |
| Common stock, par value $01 per share | 2026-02-05 |  | P |  | 38771<sup>(16)</sup> | A | 37.63<sup>(16)</sup> | 455534 | I<sup>(1)</sup> | See footnotes<sup>(1)(16)</sup> |
| Common stock, par value $01 per share | 2026-02-05 |  | P |  | 17835<sup>(17)</sup> | A | 38.67<sup>(17)</sup> | 473369 | I<sup>(1)</sup> | See footnotes<sup>(1)(17)</sup> |
| Common stock, par value $01 per share | 2026-02-05 |  | P |  | 16563<sup>(18)</sup> | A | 39.8<sup>(18)</sup> | 489932 | I<sup>(1)</sup> | See footnotes<sup>(1)(18)</sup> |
| Common stock, par value $01 per share | 2026-02-06 |  | P |  | 11183<sup>(19)</sup> | A | 35.97<sup>(19)</sup> | 501115 | I<sup>(1)</sup> | See footnotes<sup>(1)(19)</sup> |
| Common stock, par value $01 per share | 2026-02-06 |  | P |  | 19338<sup>(20)</sup> | A | 36.55<sup>(20)</sup> | 520453 | I<sup>(1)</sup> | See footnotes<sup>(1)(20)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Notes are included on Exhibit 99.1.

(2) Notes are included on Exhibit 99.1.

(3) Notes are included on Exhibit 99.1.

(4) Notes are included on Exhibit 99.1.

(5) Notes are included on Exhibit 99.1.

(6) Notes are included on Exhibit 99.1.

(7) Notes are included on Exhibit 99.1.

(8) Notes are included on Exhibit 99.1.

(9) Notes are included on Exhibit 99.1.

(10) Notes are included on Exhibit 99.1.

(11) Notes are included on Exhibit 99.1.

(12) Notes are included on Exhibit 99.1.

(13) Notes are included on Exhibit 99.1.

(14) Notes are included on Exhibit 99.1.

(15) Notes are included on Exhibit 99.1.

(16) Notes are included on Exhibit 99.1.

(17) Notes are included on Exhibit 99.1.

(18) Notes are included on Exhibit 99.1.

(19) Notes are included on Exhibit 99.1.

(20) Notes are included on Exhibit 99.1.

**Remarks:**
Exhibit List:

Exhibit 99.1 - Explanation of Responses
Exhibit 99.2 - Joint Filer Information
Exhibit 99.3 - Joint Filers' Signature

**Signature:** Suvretta Capital Management, LLC; By: /s/ Andrew Nathanson, General Counsel & Chief Compliance Officer  
**Date:** 2026-02-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**